Revolutionizing vaccine discovery: new data validates evaxion ai platform, offering promise to reduce risk and cost in infectious disease vaccine development

Copenhagen, denmark, sept. 11, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) ("evaxion" or the "company"), a clinical-stage biotechnology company specializing in the development of ai-powered immunotherapies, has achieved a groundbreaking milestone in vaccine discovery with the validation of its ai-powered vaccine discovery platform, edentm. data will be shared at the vaccines europe conference in berlin, germany, taking place from september 14th to 15th.
EVAX Ratings Summary
EVAX Quant Ranking